Protagenic Therapeutics Inc PTIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTIX is a good fit for your portfolio.
News
-
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
-
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Trading Information
- Previous Close Price
- $0.74
- Day Range
- $0.70–0.73
- 52-Week Range
- $0.68–2.22
- Bid/Ask
- $0.70 / $0.73
- Market Cap
- $3.12 Mil
- Volume/Avg
- 5,592 / 13,132
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.protagenic.com
Valuation
Metric
|
PTIX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.46 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
PTIX
|
---|---|
Quick Ratio | 5.43 |
Current Ratio | 5.53 |
Interest Coverage | −80.50 |
Quick Ratio
PTIX
Profitability
Metric
|
PTIX
|
---|---|
Return on Assets (Normalized) | −87.65% |
Return on Equity (Normalized) | −108.33% |
Return on Invested Capital (Normalized) | −105.90% |
Return on Assets
PTIX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Zwqxkbbcf | Zrvjc | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Grztxgzc | Jvhjpn | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Cwnjfvj | Nhjfcnj | $118.7 Bil | |||
Moderna Inc
MRNA
| Grczbbv | Scs | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Nmwmlkbqc | Dhfyx | $29.7 Bil | |||
argenx SE ADR
ARGX
| Kqvnvzxq | Syd | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Fwmfckvt | Rglwr | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Rrpwyfkjc | Mbxdf | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Bwxxtpxv | Klyt | $15.0 Bil | |||
Incyte Corp
INCY
| Sbfwyrfr | Lcbsvjf | $13.5 Bil |